Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $577.02MP/E –Yield –
Aclaris Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aclaris Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -1244.1%. For fiscal 2025 it was -829.6%, against -705.5% the year before. The highest annual figure on record is -283.1% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -829.6% | −124.1 |
| FY2024 | Dec 31, 2024 | -705.5% | −422.3 |
| FY2023 | Dec 31, 2023 | -283.1% | +9.0 |
| FY2022 | Dec 31, 2022 | -292.1% | +1051.8 |
| FY2021 | Dec 31, 2021 | -1344.0% | −556.9 |
| FY2020 | Dec 31, 2020 | -787.0% | +3030.2 |
| FY2019 | Dec 31, 2019 | -3817.2% | −1659.2 |
| FY2018 | Dec 31, 2018 | -2158.0% | +1913.5 |
| FY2017 | Dec 31, 2017 | -4071.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1249.8% | −806.8 |
| Q2 FY2026 | Jun 30, 2026 | -1320.1% | −451.9 |
| Q1 FY2026 | Mar 31, 2026 | -993.2% | +43.6 |
| Q4 FY2025 | Dec 31, 2025 | -1528.6% | −480.3 |
| Q3 FY2025 | Sep 30, 2025 | -443.0% | −268.4 |
| Q2 FY2025 | Jun 30, 2025 | -868.3% | −471.1 |
| Q1 FY2025 | Mar 31, 2025 | -1036.8% | −330.3 |
| Q4 FY2024 | Dec 31, 2024 | -1048.2% | −1039.7 |
| Q3 FY2024 | Sep 30, 2024 | -174.6% | +140.7 |
| Q2 FY2024 | Jun 30, 2024 | -397.2% | +1184.9 |
| Q1 FY2024 | Mar 31, 2024 | -706.5% | +407.5 |
| Q4 FY2023 | Dec 31, 2023 | -8.5% | +348.0 |
| Q3 FY2023 | Sep 30, 2023 | -315.2% | −210.3 |
| Q2 FY2023 | Jun 30, 2023 | -1582.1% | −238.4 |
| Q1 FY2023 | Mar 31, 2023 | -1113.9% | +179.2 |
| Q4 FY2022 | Dec 31, 2022 | -356.4% | +1162.8 |
| Q3 FY2022 | Sep 30, 2022 | -104.9% | +1169.7 |
| Q2 FY2022 | Jun 30, 2022 | -1343.7% | −348.0 |
| Q1 FY2022 | Mar 31, 2022 | -1293.1% | +325.0 |
| Q4 FY2021 | Dec 31, 2021 | -1519.3% | −685.5 |
| Q3 FY2021 | Sep 30, 2021 | -1274.6% | −539.0 |
| Q2 FY2021 | Jun 30, 2021 | -995.7% | −428.9 |
| Q1 FY2021 | Mar 31, 2021 | -1618.1% | −510.4 |
| Q4 FY2020 | Dec 31, 2020 | -833.7% | +864.3 |
| Q3 FY2020 | Sep 30, 2020 | -735.6% | +4892.0 |
| Q2 FY2020 | Jun 30, 2020 | -566.8% | +5062.5 |
| Q1 FY2020 | Mar 31, 2020 | -1107.7% | +1866.5 |
| Q4 FY2019 | Dec 31, 2019 | -1698.1% | −647.4 |
| Q3 FY2019 | Sep 30, 2019 | -5627.6% | −2699.1 |
| Q2 FY2019 | Jun 30, 2019 | -5629.3% | −4780.1 |
| Q1 FY2019 | Mar 31, 2019 | -2974.3% | −270.4 |
| Q4 FY2018 | Dec 31, 2018 | -1050.7% | +1245.0 |
| Q3 FY2018 | Sep 30, 2018 | -2928.4% | −268.8 |
| Q2 FY2018 | Jun 30, 2018 | -849.2% | – |
| Q1 FY2018 | Mar 31, 2018 | -2703.8% | – |
| Q4 FY2017 | Dec 31, 2017 | -2295.7% | – |
| Q3 FY2017 | Sep 30, 2017 | -2659.6% | – |
See a number that looks wrong?